The phase 2 study aimed to compare the safety of pembrolizumab and radiation with or without olaparib in this high-risk population.
Zin Myint, MD
Advertisement
Articles by Zin Myint, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer
2
Novel Agent Earns FDA Breakthrough Therapy Designation for HPV+ Oropharyngeal Cancer
3
Debating Camizestrant, ctDNA Monitoring, and SERENA-6 in HR+ Breast Cancer
4
Saturated Fat Intake Linked to Greater Mortality in Nonmetastatic Prostate Cancer
5